← Back to all products
GLP-1 · GIP · GCG
How Do They Compare?
Understanding the difference between GLP-1, GIP, and GCG receptor agonists.
Semaglutide
Ozempic / Wegovy
Tirzepatide
Mounjaro / Zepbound
Retatrutide ✦
No brand name yet
Receptors
GLP-1
GLP-1 + GIP
GLP-1 + GIP + GCG
Weight Loss
15–18%
20–22%
24–25%
Key Benefit
Proven, stable
Dual synergy
Triple power
Efficacy
★★★★★
★★★★★
★★★★★
Market Stage
Mature
Growth
Premium / Emerging
Clinical Data
Extensive
Strong
Promising
Semaglutide
Ozempic / Wegovy
ReceptorsGLP-1
Weight Loss15–18%
Key BenefitProven, stable
Efficacy★★★★★
Market StageMature
Clinical DataExtensive
Tirzepatide
Mounjaro / Zepbound
ReceptorsGLP-1 + GIP
Weight Loss20–22%
Key BenefitDual synergy
Efficacy★★★★★
Market StageGrowth
Clinical DataStrong
Retatrutide ✦
No brand name yet
ReceptorsGLP-1 + GIP + GCG
Weight Loss24–25%
Key BenefitTriple power
Efficacy★★★★★
Market StagePremium / Emerging
Clinical DataPromising
Why Each Matters
Semaglutide
Ozempic / Wegovy
Established safety & efficacy. Largest patient base worldwide.
Tirzepatide
Mounjaro / Zepbound
Superior results via dual GLP-1 + GIP pathway. Strong current momentum.
Retatrutide
No brand name yet
Next-generation breakthrough. Direct hepatic fat loss via GCG. First-to-market premium positioning.
TL;DR · More receptors = more weight loss. Retatrutide leads on efficacy, Semaglutide on track record, Tirzepatide on value.